Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01411293|
Recruitment Status : Completed
First Posted : August 8, 2011
Last Update Posted : January 6, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease Metabolic Syndrome Obesity||Other: Low-Fat Milk Other: Rice Milk||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||October 2013|
Experimental: Low-Fat Dairy
Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
Other: Low-Fat Milk
Participants will ingest 2 cups of low-fat milk on 1 occasion.
Active Comparator: Rice Milk
Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
Other: Rice Milk
Participants will ingest 2 cups of rice milk on 1 occasion.
- endothelial function [ Time Frame: 3 hours ]Brachial artery flow-mediated dilation will be assessed at 30 min intervals during a 3 hour postprandial period
- Biomarkers of oxidative stress and nitric oxide metabolism [ Time Frame: 3 hours ]At 30 min intervals throughout a 3 hour postprandial period, biomarkers of oxidative stress (glutathione, malondialdehyde, nitrotyrosine, and antioxidants) as well as nitric oxide metabolism (arginine, asymmetric dimethylarginine, and nitric oxide metabolites) will be evaluated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01411293
|United States, Connecticut|
|University of Connecticut|
|Storrs, Connecticut, United States, 06269|
|Principal Investigator:||Richard S Bruno, PhD, RD||University of Connecticut|